A detailed history of Bank Of America Corp transactions in Olema Pharmaceuticals, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 410,939 shares of OLMA stock, worth $3.61 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
410,939
Previous 133,395 208.06%
Holding current value
$3.61 Million
Previous $1.44 Million 239.99%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.41 - $16.46 $2.89 Million - $4.57 Million
277,544 Added 208.06%
410,939 $4.91 Million
Q2 2024

Aug 14, 2024

SELL
$8.73 - $13.99 $1.69 Million - $2.71 Million
-193,424 Reduced 59.18%
133,395 $1.44 Million
Q1 2024

May 15, 2024

BUY
$10.95 - $16.62 $3.14 Million - $4.77 Million
286,709 Added 714.81%
326,819 $3.7 Million
Q4 2023

Feb 14, 2024

BUY
$10.53 - $17.14 $187,760 - $305,623
17,831 Added 80.04%
40,110 $562,000
Q2 2023

Aug 14, 2023

SELL
$3.22 - $9.65 $22,907 - $68,650
-7,114 Reduced 24.2%
22,279 $201,000
Q1 2023

May 12, 2023

BUY
$2.55 - $4.97 $2,657 - $5,178
1,042 Added 3.68%
29,393 $101,000
Q4 2022

Feb 10, 2023

BUY
$2.27 - $3.76 $32,840 - $54,395
14,467 Added 104.2%
28,351 $69,000
Q3 2022

Nov 14, 2022

SELL
$2.72 - $5.88 $108,517 - $234,588
-39,896 Reduced 74.18%
13,884 $38,000
Q2 2022

Aug 12, 2022

SELL
$2.04 - $4.61 $208,492 - $471,151
-102,202 Reduced 65.52%
53,780 $218,000
Q1 2022

May 16, 2022

BUY
$3.89 - $9.43 $158,774 - $384,894
40,816 Added 35.44%
155,982 $664,000
Q4 2021

Feb 08, 2022

BUY
$8.75 - $30.71 $786,310 - $2.76 Million
89,864 Added 355.17%
115,166 $1.08 Million
Q3 2021

Nov 15, 2021

BUY
$22.96 - $30.13 $494,673 - $649,150
21,545 Added 573.46%
25,302 $698,000
Q2 2021

Sep 13, 2021

BUY
$21.15 - $36.14 $79,460 - $135,777
3,757 New
3,757 $105,000

Others Institutions Holding OLMA

About Olema Pharmaceuticals, Inc.


  • Ticker OLMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,419,600
  • Market Cap $355M
  • Description
  • Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...
More about OLMA
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.